Global Transdermal Skin Patches Market Assessment, By Type [Single-layer Drug-in-Adhesive Patches, Multi-layer Drug-in-Adhesive Patches, Matrix Patches, Microneedle Patches, Others], By Application [Pain Management, Hormonal Therapy, Cardiovascular Diseases, Neurological Disorder, Smoking Reduction and Cessation Aid, Others], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], By Region, Opportunities and Forecast, 2017-2031F

Global transdermal skin patches market is projected to witness a CAGR of 5.20% during the forecast period 2024-2031, growing from USD 8.12 billion in 2023 to USD 12.18 billion in 2031. The market demand for transdermal skin patches is anticipated to thrive drastically in the forecast years due to the rising prevalence of chronic diseases, such as neurological and cardiovascular diseases.

Transdermal skin patches represent novel drug delivery systems. These systems deliver medicine to a patient through the skin while allowing the controlled release of medication into the bloodstream. The skin patches adhere to a patient's skin and draw active ingredients from the agent into the skin by using various mechanisms, including permeation enhancers or microneedles. It shows some advantages over conventional preparations, such as first-pass digestion and avoidance of gastric/enzymatic drug degradation, with better patient compliance, fewer side effects, and always maintaining its drug levels in the body. Some of the primary applications are pain management, replacement of hormones, and smoking cessation.

Patch therapy options are expanding, offering more comfortable and effective treatments. Demand for transdermal patches is driven by the preference for non-invasive drug delivery, improving patient compliance and comfort. Additionally, the rise in chronic diseases like diabetes and cardiovascular conditions is increasing the need for these patches, likely fueling growth in the global market. For instance, in September 2023, Corium, LLC, a biopharmaceutical company, published data reinforcing that ADLARITY (donepezil transdermal system) is a promising transdermal patch with favorable skin adhesion and tolerability. ADLARITY was approved in March 2022 by the United States Food and Drug Administration (US FDA) for the treatment of mild, moderate, and severe dementia of Alzheimer’s disease. Donepezil, an acetylcholinesterase inhibitor and the active ingredient in the oral drug Aricept is the most prescribed Alzheimer's dementia medication in the United States.

Increased Demand for Non-Invasive Delivery Brings Market Growth

Rising demand for non-invasive delivery methods significantly drives growth in the transdermal skin patch market. The healthcare sector is increasingly focused on pain-free drug administration, appealing to patients seeking less invasive therapies. Today’s patients prefer options that minimize discomfort, avoiding needles or surgical procedures. The healthcare landscape appeals to less painful drug administrations. Patients these days would want therapies that minimize the discomfort and avoid going through some form of surgery or sticking needles into their bodies. These alternatives include transdermal skin patches, comforted by ease of application because they can be self-administered at home without the need for professional assistance. The reasons are particularly pertinent to the case of chronic diseases that require long-term treatment. Patients prefer painless and user-friendly regimens. In addition, non-invasive delivery is less likely to cause complications such as infection or allergic reactions associated with injections. As the healthcare system continues to draw more focus on pain control and patient compliance, there is likely to be greater demand for non-invasive delivery systems that enhance compliance, further fueling the innovation of drug delivery technologies. For instance, in October 2023, Luye Pharma Group received approval for Rivastigmine transdermal patch from China’s National Medical Products Administration (NMPA). The patches are proven to be a promising treatment for symptomatic mild to moderate Alzheimer’s disease (AD) and have been widely adopted in Europe.

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a major growth driver for the transdermal skin patch market, which usually requires long-term management and consistent therapeutic intervention; the growth rate for the transdermal skin patches market is very high. For example, diabetes, hypertension, and chronic pain disorders require precise and effective delivery systems to enhance compliance among patients and ensure optimal health outcomes. The convenience offered through sustained-release medication in transdermal patches is a great solution, as it maintains constant levels of drugs in the bloodstream and decreases the dosing frequency. This is especially attractive to patients on multiple medications or on complex regimens. As the aging population becomes more susceptible to chronic diseases, demand for innovative delivery systems like transdermal skin patches. These patches effectively manage chronic conditions while prioritizing patient comfort and compliance. This trend is expected to drive substantial transdermal skin patch market growth.

A report published by the Shanghai Municipal People’s Government highlights chronic disease population among the elderly as a major public health issue in China. The report stated that in 2023, among China’s 190 million elderly population, 75% are suffering from at least one chronic condition, while 43% are managing two or more chronic diseases. This underlines the urgent need for health strategies focused on chronic disease management in China’s aging population.

Multi-Layer Drug-in-Adhesive Patches to Dominate the Transdermal Skin Patches Market

The multi-layer drug-in-adhesive patches segment is anticipated to assert strong dominance in the transdermal skin patches market. The drug-in-adhesive patches combine various layers of drug and adhesive for prolonged delivery of active ingredients and offer active ingredient stability with less skin irritation, thereby improving patient comfort and compliance. On the rise of personalized treatment options and efficient management of chronic conditions, the versatility and efficiency offered by multilayer drug-in-adhesive patches are ideal for choice among patients and healthcare providers. These are the major factors driving the growth of the transdermal skin patches market.

Moreover, technological advancements and new product launches will further fuel the segment's growth in the market. For instance, in September 2023, Zydus Lifesciences Limited received approval from the United States Food and Drug Administration for Norelgestromin and Ethinyl Estradiol Transdermal System. These patches provide combination hormone medication and are used to prevent pregnancy.

North America Dominates Transdermal Skin Patches Market

North American region is anticipated to dominate the transdermal skin patches market for several reasons, including advanced healthcare infrastructure, a high level of awareness, and the most significant investment in research and development in the region. The strong pharmaceutical sector in the region has played an important role in the innovation and commercialization of new transdermal delivery systems to target the ever-growing demand for efficient and easy forms of treatment. The prevalence of chronic diseases like diabetes and cardiovascular conditions has also pushed the development of safe methods of delivering medication, thereby improving patient compliance. For instance, in August 2024, Zydus Lifesciences Limited received US FDA approval for its Scopolamine Transdermal System, a patch indicated to prevent nausea and vomiting associated with anesthesia, opioid medications, surgery, and motion sickness. The Scopolamine Transdermal System achieved annual sales of USD 69.6 million in the U.S.

Download Free Sample Report

Future Market Scenario (2024-2031F)

The future scenario for transdermal skin patches is promising, driven primarily by ongoing technological advancements and evolving healthcare needs. Growing demand for non-invasive drug delivery methods, such as micro needle patches and smart delivery systems, is expected to increase the effectiveness and flexibility of transdermal therapies. The increasing prevalence of chronic diseases and the aging population are likely to drive demand for long-acting products that help improve patient compliance as well as outcomes from therapies. Markets are set to expand into other areas, such as pain management, hormone therapies, and vaccinations, hence driving the growth of the transdermal patches market.

For instance, in January 2024, Starton Therapeutics Inc., a biotechnology company, launched STARSILON, a transdermal patch delivery platform. This adhesive transdermal technology enables continuous, low-dose delivery of various molecules, including those targeting oncology, inflammation, and central nervous system (CNS)conditions. The platform aims to enhance efficacy, reduce toxicity, and improve patient tolerance, opening new opportunities for expanded therapeutic applications.             

Report Scope

“Transdermal Skin Patches Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global transdermal skin patches market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2023
Historical Period	2017-2022
Forecast Period	2024-2031
Projected Growth Rate	CAGR of 5.20% between 2024 and 2031
Revenue Forecast in 2031	USD 12.18 billion
Segments Covered	Type, Application, Distribution Channel
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profile	Teva Pharmaceuticals Industries Ltd., Novartis AG, Johnson & Johnson Services, Inc., Viatris Inc., Samyang Biopharmaceuticals Corp., Agile Therapeutics Inc., Purdue Pharma L.P., Tiekoku Pharma USA Inc., Hisamitsu Pharmaceutical Co., Inc, Luye Pharma Group, Zydus Lifesciences Limited.
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global transdermal skin patches market has been segmented into the following categories: 

• By Type
  • Single-Layer Drug-in-Adhesive Patches
  • Multi-Layer Drug-in-Adhesive Patches
  • Matrix Patches
  • Microneedle Patches
  • Others
• By Application
  • Pain Management
  • Hormonal Therapy
  • Cardiovascular Diseases
  • Neurological Disorder
  • Smoking Reduction and Cessation Aid
  • Others
• By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Players Landscape and Outlook

The global transdermal skin patches market is highly competitive, with leading and emerging players vying to capture the elevating opportunities. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market also fosters several smaller players, which operate through collaborations with other players to cater to a larger market.

In August 2024, Agile Therapeutics, Inc. completed the acquisition of Indus Pharma, S.L., a global pharmaceutical group based in Spain. Agile Therapeutics specializes in addressing unmet women's healthcare needs for contraception. Their lead product is Twirla, a prescription contraceptive that delivers levonorgestrel and ethinyl estradiol through a non-daily transdermal patch.

In September 2023, Yaral Pharma Inc. (Yaral Pharma), a subsidiary of Institute Biochimique SA (IBSA), launched Lidocaine Patch 5% for the treatment of pain management and inflammation.

Key Players Operating in the Global Transdermal Skin Patches Market are:

• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• Johnson & Johnson Services, Inc.
• Viatris Inc.
• Samyang Biopharmaceuticals Corp.
• Agile Therapeutics Inc.
• Purdue Pharma L.P.
• Tiekoku Pharma USA Inc.
• Hisamitsu Pharmaceutical Co., Inc
• Luye Pharma Group
• Zydus Lifesciences Limited

Markets and Data’s report answers the following questions:

• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and the market size and growth of each segment?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global transdermal skin patches market, you may approach our team at info@marketsandata.com.